ERBB2 and non-small cell lung carcinoma: It is engineered with a topoisomerase I inhibitor payload and a novel linker system that minimizes premature cleavage and off-target toxicity, contributing to its favorable safety profile and antitumor activity in HER2-mutant NSCLC (142, 143).